Triveni Bio closes a $65M Series C to fund two eczema drug candidates targeting kallikreins and IL-13, with Phase 2a data on lead asset TRIV-509 expected by year-end.
Triveni Bio announced a $65 million Series C after its second asset for eczema entered clinical studies last month.
The Series C was co-led by …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
Biogen adds more immune drugs in $1B buyout of secretive startup Raythera
Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026
cAMPfield lands $180M to build gut disease drug
Kardigan extends biotech’s streak of big IPOs with $400M haul
Year-End Report 2025-2026
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and…
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which…
Turn Therapeutics' topical GX-03 hit EASI-50 in 93% of eczema patients at four weeks.
Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according…
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
Kanvas Biosciences announced a $48 million Series A funding round, which will support a clinical trial later this year for the…
